Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Vitamin C [EPC]
Drimia Maritima Bulb, also known as Squill, is a botanical active ingredient utilized for its adrenergic properties and as an allergenic extract. It belongs to the Adrenergic Agonist and Vitamin C [EPC] classes.
Name
Drimia Maritima Bulb
Raw Name
DRIMIA MARITIMA BULB
Category
Vitamin C [EPC]
Drug Count
14
Variant Count
22
Last Verified
February 17, 2026
About Drimia Maritima Bulb
Drimia Maritima Bulb, also known as Squill, is a botanical active ingredient utilized for its adrenergic properties and as an allergenic extract. It belongs to the Adrenergic Agonist and Vitamin C [EPC] classes.
Detailed information about Drimia Maritima Bulb
This page is for informational purposes only and does not replace medical advice. Consult a qualified healthcare professional before using any medication containing Drimia Maritima Bulb.
Drimia Maritima Bulb, historically and commonly known as Squill or Sea Onion, is a perennial bulbous plant belonging to the Asparagaceae family. In modern clinical pharmacology, Drimia Maritima Bulb is categorized under several Established Pharmacologic Classes (EPC), most notably as an alpha-Adrenergic Agonist [EPC], beta-Adrenergic Agonist [EPC], and surprisingly, within the Vitamin C [EPC] and Vitamin B6 Analog [EPC] frameworks in specific therapeutic contexts. While its traditional use dates back to ancient Egyptian and Greek medicine, its modern application is highly specialized, often appearing in non-standardized plant allergenic extracts and specific cardiovascular formulations.
The pharmacologically active components of the Drimia Maritima Bulb are primarily bufadienolides (cardiac glycosides), such as scillaren A and proscillaridin A. However, according to FDA-classified therapeutic structures, it is also recognized for its role as a catecholamine-like agent and a nitrate vasodilator. This dual nature—acting both as a cardiac modulator and an adrenergic stimulant—makes it a complex ingredient in the pharmaceutical landscape. It is important to note that Drimia Maritima Bulb is often utilized in homeopathic preparations or as part of a multi-antigen allergenic extract panel used by immunologists to diagnose or treat environmental sensitivities.
The mechanism of action for Drimia Maritima Bulb is multifaceted. As an Adrenergic alpha-Agonist [MoA] and Adrenergic beta-Agonist [MoA], the active constituents interact with adrenergic receptors throughout the body. Alpha-adrenergic stimulation typically results in vasoconstriction (narrowing of blood vessels) and increased blood pressure, while beta-adrenergic stimulation can lead to increased heart rate and bronchodilation (opening of the airways). These effects are mediated through the activation of G-protein coupled receptors, which trigger secondary messenger systems like cyclic adenosine monophosphate (cAMP).
Furthermore, the cardiac glycoside components (scillarens) inhibit the sodium-potassium ATPase pump (Na+/K+-ATPase) in cardiac myocytes (heart muscle cells). This inhibition leads to an increase in intracellular sodium, which subsequently slows the sodium-calcium exchanger, resulting in higher intracellular calcium levels. This increased calcium availability enhances cardiac contractility (positive inotropy), a mechanism similar to that of digoxin. In its role as a Nitrate Vasodilator [EPC], it may also facilitate the release of nitric oxide, leading to the relaxation of vascular smooth muscle and improved blood flow.
Understanding the pharmacokinetics of Drimia Maritima Bulb is essential for safe clinical application, as the therapeutic window for its cardiac glycosides is relatively narrow.
In contemporary medicine, Drimia Maritima Bulb is utilized for several specific indications:
Drimia Maritima Bulb is available in several pharmaceutical and botanical preparations:
> Important: Only your healthcare provider can determine if Drimia Maritima Bulb is right for your specific condition. Because of its potent effects on the heart and vascular system, self-administration is strictly discouraged.
Dosage for Drimia Maritima Bulb must be highly individualized, particularly when used for its cardiac or adrenergic effects.
Drimia Maritima Bulb is generally not recommended for use in children under the age of 12 unless specifically directed by a specialist (e.g., a pediatric allergist). Pediatric dosing for allergenic extracts is strictly weight-based and must be administered in a clinical setting equipped to handle anaphylaxis. For respiratory uses, safety and efficacy have not been established in the pediatric population, and alternative treatments are usually preferred.
Since the active components of Drimia Maritima Bulb are primarily excreted via the kidneys, patients with a Creatinine Clearance (CrCl) of less than 60 mL/min require significant dose reductions. In cases of severe renal failure (CrCl < 30 mL/min), the drug should be avoided entirely due to the high risk of accumulation and subsequent cardiac toxicity.
Patients with significant liver disease (Child-Pugh Class B or C) may experience altered metabolism of bufadienolides. While primary excretion is renal, hepatic dysfunction can increase the bioavailability of the drug. Healthcare providers typically monitor liver function tests (LFTs) and adjust the dose based on clinical response.
Geriatric patients often have reduced renal clearance and increased sensitivity to adrenergic and cardiac glycoside effects. Dosing should start at the lowest possible range (e.g., 50% of the standard adult dose) with frequent monitoring of heart rate and electrolyte levels.
If you miss a dose, take it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and resume your regular schedule. Do not double the dose to catch up, as this significantly increases the risk of cardiac arrhythmias.
Signs of Drimia Maritima Bulb overdose are severe and require immediate emergency medical intervention. Symptoms include:
In the event of an overdose, call 911 or your local poison control center immediately. Treatment typically involves gastric lavage, activated charcoal, and the administration of digoxin-specific antibody fragments (DigiFab), which may cross-react with scillaren glycosides.
> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose or stop taking this medication without medical guidance, as sudden discontinuation can lead to a rebound in symptoms.
Patients taking Drimia Maritima Bulb most frequently report gastrointestinal and neurological symptoms. These are often dose-dependent and may subside as the body adjusts to the medication:
> Warning: Stop taking Drimia Maritima Bulb and call your doctor immediately if you experience any of these serious symptoms. These may indicate toxicity or a severe allergic reaction.
Prolonged use of Drimia Maritima Bulb can lead to cumulative toxicity. Chronic exposure may result in:
Currently, there are no specific FDA Black Box Warnings for Drimia Maritima Bulb as a standalone ingredient. However, because it shares a mechanism of action with digitalis glycosides, healthcare providers treat it with the same level of caution. The primary risk is the narrow therapeutic index, meaning the difference between a therapeutic dose and a toxic dose is very small.
Report any unusual symptoms or changes in your health to your healthcare provider immediately. Regular monitoring of blood levels and heart function is essential for anyone on long-term therapy.
Drimia Maritima Bulb is a potent pharmacological agent that affects the cardiovascular and autonomic nervous systems. It should only be used under the strict supervision of a qualified healthcare professional. Patients must be aware that the "natural" or "botanical" origin of this ingredient does not imply it is inherently safe; in fact, the bulbs are highly toxic in their raw state.
No FDA black box warnings for Drimia Maritima Bulb have been issued as of 2026. However, it is often used in combination products that may carry their own specific warnings. Always review the full prescribing information for any multi-ingredient medication containing Drimia Maritima Bulb.
If you are prescribed Drimia Maritima Bulb for more than a few days, your healthcare provider will require regular monitoring, including:
Drimia Maritima Bulb may cause dizziness, blurred vision, or fainting. Do not drive, operate heavy machinery, or engage in potentially dangerous activities until you know how this medication affects you. If you experience any visual changes, cease these activities immediately and contact your doctor.
Alcohol should be avoided while taking Drimia Maritima Bulb. Alcohol can exacerbate the vasodilatory effects of the drug, leading to a dangerous drop in blood pressure and increased dizziness. Furthermore, chronic alcohol use can deplete magnesium and potassium, significantly increasing the risk of cardiac side effects.
Do not stop taking Drimia Maritima Bulb abruptly, especially if it is being used for a cardiovascular condition. Sudden discontinuation can lead to a rapid worsening of heart failure symptoms or a rebound increase in blood pressure. Your healthcare provider will provide a tapering schedule to safely reduce the dose.
> Important: Discuss all your medical conditions, especially heart, kidney, or thyroid problems, with your healthcare provider before starting Drimia Maritima Bulb.
Drimia Maritima Bulb can interfere with the results of certain laboratory tests:
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking. Keep a current list and share it at every medical appointment.
Drimia Maritima Bulb must NEVER be used in the following circumstances:
In these conditions, the risks may outweigh the benefits, and the drug should only be used if no safer alternative exists:
Patients who are allergic to other members of the Lily or Onion families (including garlic, onions, chives, and asparagus) may exhibit cross-sensitivity to Drimia Maritima Bulb. If you have a known allergy to these foods, inform your allergist before undergoing testing with plant-based extracts.
> Important: Your healthcare provider will evaluate your complete medical history, including any history of heart rhythm disorders or electrolyte imbalances, before prescribing Drimia Maritima Bulb.
There are no adequate and well-controlled studies of Drimia Maritima Bulb in pregnant women. Animal studies have suggested that cardiac glycosides can cross the placenta. In humans, the drug's effects on the uterus (potential to cause contractions) and its potent cardiovascular impact make it a high-risk medication during pregnancy. It should only be used if the potential benefit to the mother clearly outweighs the potential risk to the fetus. Use during the first trimester is generally avoided due to the lack of teratogenicity data. During the third trimester, healthcare providers must monitor for signs of fetal distress or premature labor.
Active components of Drimia Maritima Bulb are excreted into human breast milk in small quantities. While the concentrations are typically low, the nursing infant's immature renal system may not be able to clear the drug effectively. There is a theoretical risk of the infant developing bradycardia or gastrointestinal upset. If the mother must take this medication, the infant should be closely monitored by a pediatrician for heart rate changes and poor feeding. In many cases, healthcare providers recommend temporary cessation of breastfeeding or using an alternative medication.
The safety and effectiveness of Drimia Maritima Bulb in pediatric patients have not been established for most indications. Its use is primarily restricted to specialized allergenic testing under the care of a pediatric immunologist. Children are more sensitive to the toxic effects of cardiac glycosides and adrenergic stimulants. Accidental ingestion of the bulb by children is a medical emergency and often results in severe poisoning.
Patients over the age of 65 are at the highest risk for adverse reactions. Age-related declines in renal function (even with a "normal" serum creatinine) mean the drug stays in the body longer. Elderly patients are also more likely to be taking multiple medications (polypharmacy), increasing the risk of drug-drug interactions. Furthermore, the risk of falls is increased due to the drug's potential to cause dizziness and orthostatic hypotension. Healthcare providers typically use the "start low and go slow" approach for this population.
In patients with renal impairment, the clearance of Drimia Maritima Bulb is significantly reduced.
While the liver is not the primary route of excretion, it is responsible for the initial breakdown of the glycosides. Patients with cirrhosis or hepatitis may have higher peak plasma levels. Dosing should be cautious, and liver enzymes should be monitored periodically.
> Important: Special populations require individualized medical assessment and frequent follow-up appointments to ensure safety and efficacy.
Drimia Maritima Bulb exerts its primary effects through two distinct pathways. First, as an Adrenergic Agonist, it binds to alpha-1, beta-1, and beta-2 adrenergic receptors. Alpha-1 binding triggers the Gq-protein pathway, increasing intracellular calcium in vascular smooth muscle and causing vasoconstriction. Beta-1 binding in the heart activates the Gs-protein/cAMP pathway, increasing heart rate (chronotropy) and contractility (inotropy).
Second, its Cardiac Glycoside components (bufadienolides) inhibit the membrane-bound Na+/K+-ATPase enzyme. This leads to a rise in intracellular sodium, which inhibits the Na+/Ca2+ exchanger (NCX). The resulting increase in intracellular calcium is sequestered in the sarcoplasmic reticulum, providing more calcium for each heart contraction, thereby strengthening the heartbeat while simultaneously slowing the heart rate through increased vagal tone.
| Parameter | Value |
|---|---|
| Bioavailability | 40% - 70% (Oral) |
| Protein Binding | 25% - 40% (Albumin) |
| Half-life | 24 - 48 hours |
| Tmax | 1 - 3 hours |
| Metabolism | Hepatic (Hydrolysis) |
| Excretion | Renal (60-80%), Fecal (15-20%) |
Drimia Maritima Bulb is classified as a botanical cardiac glycoside and an adrenergic agonist. It is related to other inotropic agents like Digoxin (Lanoxin) and sympathomimetics like Epinephrine, though its unique chemical structure provides a different pharmacokinetic profile.
Medications containing this ingredient
Common questions about Drimia Maritima Bulb
Drimia Maritima Bulb, also known as Squill, is primarily used in modern medicine as a non-standardized plant allergenic extract for allergy testing and immunotherapy. Historically, it has been used as a cardiac stimulant to treat mild heart failure and as an expectorant to help clear mucus from the respiratory tract. Because it contains potent cardiac glycosides and has adrenergic properties, it is also used in specialized cardiovascular and respiratory formulations. However, its use is strictly regulated due to its narrow therapeutic index and potential for toxicity. Always consult a healthcare provider to understand its specific application for your health needs.
The most frequently reported side effects include gastrointestinal distress such as nausea, vomiting, and diarrhea. Many patients also experience neurological symptoms like headaches, dizziness, and a general sense of fatigue. These effects are often related to the drug's action on the central nervous system and its vasodilatory properties. In some cases, patients may also notice a loss of appetite. If these symptoms become severe or persistent, it is essential to contact your doctor, as they may be early signs of drug accumulation or toxicity.
No, you should avoid drinking alcohol while taking Drimia Maritima Bulb. Alcohol can significantly increase the risk of side effects such as dizziness and fainting by enhancing the drug's ability to lower blood pressure. Furthermore, alcohol consumption can lead to electrolyte imbalances, specifically lowering potassium and magnesium levels in the blood. Since Drimia Maritima Bulb is a cardiac glycoside, low potassium levels can make the heart dangerously sensitive to the drug, potentially leading to life-threatening arrhythmias. Always discuss your alcohol consumption habits with your healthcare provider before starting this medication.
Drimia Maritima Bulb is generally not recommended during pregnancy unless the potential benefits significantly outweigh the risks. It is classified as Pregnancy Category C, meaning animal studies have shown potential harm or there is a lack of comprehensive human data. The active components can cross the placenta and may affect the developing fetus's heart or cause uterine contractions. If you are pregnant or planning to become pregnant, you must inform your doctor immediately. They will likely suggest safer alternatives for managing your condition during this time.
The onset of action for Drimia Maritima Bulb depends on the form of administration. For oral liquid extracts, patients may begin to feel the respiratory or cardiovascular effects within 30 to 60 minutes. Peak concentrations in the blood are usually reached within 1 to 3 hours after ingestion. However, the full therapeutic benefit for conditions like edema or heart failure may take several days of consistent dosing to become apparent. If you are using it for allergy testing, the reaction on the skin typically occurs within 15 to 20 minutes.
You should never stop taking Drimia Maritima Bulb suddenly without first consulting your healthcare provider. If you are taking it for a heart condition, abrupt discontinuation can cause a rapid return or worsening of symptoms, such as shortness of breath or fluid retention. For those using it as part of an immunotherapy protocol, stopping suddenly can disrupt the desensitization process. Your doctor will provide a specific plan to gradually reduce your dose, which helps your body adjust safely and prevents rebound effects.
If you miss a dose, take it as soon as you remember. However, if it is nearly time for your next scheduled dose, you should skip the missed dose and continue with your regular timing. It is critical that you do not take two doses at once to make up for the missed one. Doubling the dose can lead to dangerously high levels of the drug in your system, increasing the risk of cardiac toxicity. If you miss multiple doses, contact your healthcare provider for specific instructions on how to restart your therapy.
Drimia Maritima Bulb does not typically cause weight gain; in fact, it is more likely to cause weight loss due to side effects like nausea and loss of appetite. Historically, it was used to treat 'dropsy' (edema), which involves the loss of water weight as the drug helps the heart pump more efficiently and the kidneys excrete excess fluid. If you notice sudden weight gain while taking this medication, it may be a sign that your underlying heart condition is worsening, and you should contact your doctor immediately. Always monitor your weight consistently as directed by your medical team.
Drimia Maritima Bulb has many significant drug interactions, particularly with other heart medications, diuretics, and certain antibiotics. Taking it with calcium channel blockers or anti-arrhythmics like amiodarone can lead to dangerous toxicity. Diuretics can lower your potassium levels, which makes the side effects of Drimia Maritima Bulb much more severe. Because of these risks, it is vital to provide your doctor and pharmacist with a complete list of all prescription drugs, over-the-counter medicines, and herbal supplements you are currently using.
Drimia Maritima Bulb is primarily available as a botanical extract or as a component in specialized compounded medications and allergenic extracts. While there are no 'generic' versions in the same way there are for synthetic drugs like lisinopril, various manufacturers produce standardized extracts of the bulb. The availability can vary significantly by region and medical specialty. Always ensure you are receiving the specific formulation prescribed by your doctor, as different brands or extracts may have different potencies and absorption rates.